Abstract INTRODUCTION: Intralesional treatment for cutaneous leishmaniasis has been applied for over 30 years at the Oswaldo Cruz Foundation, Rio de Janeiro, with good therapeutic results and without relevant systemic toxicity. METHODS Meglumine antimoniate was injected subcutaneously, using a long medium-caliber needle (for example, 30mm × 0.8mm); patients received 1-3 injections, with 15-day intervals. RESULTS The technique is described in detail sufficient to enable replication. CONCLUSIONS: The treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate is a simple, effective, and safe technique, which may be used in basic healthcare settings
acute cutaneous leishmaniasis(ACL) is an endemic disease in developing countries.the first line drug...
Abstract. Cutaneous leishmaniasis, known as chiclero’s ulcer in southeastern Mexico, is characterize...
Human cutaneous leishmaniasis (CL) and mucous leishmaniasis (ML) are highly endemic in Isiboro Secur...
Abstract Cutaneous leishmaniasis (CL) is a high-morbidity, vector-borne disease endemic to Colombia....
Although intralesional meglumine antimoniate (MA) infiltration is considered an option for cutaneous...
The standard of care for cutaneous leishmaniasis includes the intramuscular/intravenous administrati...
Abstract. We evaluated the effectiveness and safety of intralesional meglumine antimoniate (MA) in 2...
BACKGROUND Despite its recognised toxicity, antimonial therapy continues to be the first-line drug f...
Cutaneous leishmaniasis is a self-limited infection of skin caused by the genus Leishmania, a protoz...
BACKGROUND American tegumentary leishmaniasis (ATL) is a non-lethal parasitic disease that presents ...
Cutaneous leishmaniasis (CL) is treated with painful intralesional injections of meglumine antimonia...
Abstract INTRODUCTION: Favorable responses in American tegumentary leishmaniasis (ATL) patients to ...
Objective: The objective of this study is to compare the efficacy and safety of Intralesional Meglum...
The mainstays of cutaneous leishmaniasis (CL) treatment, in several world regions, are pentavalent a...
utaneous leishmaniasis (CL) is a specific skin infection caused by Leishmania parasite and is endemi...
acute cutaneous leishmaniasis(ACL) is an endemic disease in developing countries.the first line drug...
Abstract. Cutaneous leishmaniasis, known as chiclero’s ulcer in southeastern Mexico, is characterize...
Human cutaneous leishmaniasis (CL) and mucous leishmaniasis (ML) are highly endemic in Isiboro Secur...
Abstract Cutaneous leishmaniasis (CL) is a high-morbidity, vector-borne disease endemic to Colombia....
Although intralesional meglumine antimoniate (MA) infiltration is considered an option for cutaneous...
The standard of care for cutaneous leishmaniasis includes the intramuscular/intravenous administrati...
Abstract. We evaluated the effectiveness and safety of intralesional meglumine antimoniate (MA) in 2...
BACKGROUND Despite its recognised toxicity, antimonial therapy continues to be the first-line drug f...
Cutaneous leishmaniasis is a self-limited infection of skin caused by the genus Leishmania, a protoz...
BACKGROUND American tegumentary leishmaniasis (ATL) is a non-lethal parasitic disease that presents ...
Cutaneous leishmaniasis (CL) is treated with painful intralesional injections of meglumine antimonia...
Abstract INTRODUCTION: Favorable responses in American tegumentary leishmaniasis (ATL) patients to ...
Objective: The objective of this study is to compare the efficacy and safety of Intralesional Meglum...
The mainstays of cutaneous leishmaniasis (CL) treatment, in several world regions, are pentavalent a...
utaneous leishmaniasis (CL) is a specific skin infection caused by Leishmania parasite and is endemi...
acute cutaneous leishmaniasis(ACL) is an endemic disease in developing countries.the first line drug...
Abstract. Cutaneous leishmaniasis, known as chiclero’s ulcer in southeastern Mexico, is characterize...
Human cutaneous leishmaniasis (CL) and mucous leishmaniasis (ML) are highly endemic in Isiboro Secur...